Wyeth v. Levine

Wyeth v. Levine Wyeth v. Levine is a 2009 Supreme Court decision addressing preemption of state-law failure-to-warn claims by Food and Drug Administration approval of drug labeling. The Court held that a plaintiff injured by a properly prescribed drug could pursue common-law fraud-on-the-label and negligence claims despite FDA approval, rejecting broad preemption arguments. The case arose from an amputation after an injection of the drug Phenergan produced by Wyeth, implicating statutes, regulatory agencies, and doctrine central to United States Supreme Court jurisprudence.

Background

Diana Levine, a professional musician from Montana, received an injection of promethazine (marketed as Phenergan) manufactured by Wyeth Pharmaceuticals, an affiliate of Wyeth, leading to ischemic gangrene and subsequent amputation of her arm. Levine sued in Vermont state court under state tort law, alleging that inadequate labeling and failure to provide a black box warning about administration risks caused her injury. Wyeth invoked preemption under the Supremacy Clause of the United States Constitution and argued that approval of the drug label by the Food and Drug Administration protected it from liability, citing interactions with FDA review staff in Rockville, Maryland and regulatory procedures under the Federal Food, Drug, and Cosmetic Act. The factual record included testimony about informed consent practices in emergency medicine, the role of prescribing physicians such as Levine’s treating doctor, and prior adverse event reporting to the FDA's MedWatch program.

Supreme Court Decision

The Supreme Court, in an opinion by Justice John Paul Stevens, affirmed the Vermont Supreme Court and rejected Wyeth’s preemption defense. The majority held that FDA approval of a drug label does not automatically preempt state-law claims, distinguishing between express preemption in statutes like the Medical Device Amendments of 1976 and implied conflict preemption. The plurality emphasized that manufacturers can pursue the FDA's formal label-change procedures, referencing the New England Journal of Medicine debates about regulatory update mechanisms, but found no clear evidence that the FDA would have rejected stronger warnings. Dissenting opinions, including one by Justice Samuel Alito joined in part by Justice Antonin Scalia, warned about judicial disruption of the federal regulatory scheme and cited deference principles linked to Chevron U.S.A., Inc. v. Natural Resources Defense Council, Inc. and separation of powers doctrines adjudicated by the Court in earlier terms.

Legal Principles and Precedents

The decision applied preemption doctrine developed in cases such as Geier v. American Honda Motor Co. and Buckman Co. v. Plaintiffs' Legal Committee, navigating tensions between conflict preemption, express preemption, and federal agency authority. The Court distinguished Buckman’s holding that certain fraud-on-the-FDA claims are precluded because they interfere with exclusive federal enforcement activity, while preserving ordinary state tort claims that complement federal oversight. The majority relied on interpretive canons from Marbury v. Madison and administrative-law principles discussed in Skidmore v. Swift & Co. and Chevron, emphasizing the evidentiary record of FDA communications, and invoked substantive due process and Tenth Amendment considerations insofar as states retain traditional police powers exercised through tort law.

Impact on Drug Regulation and Manufacturers

Wyeth v. Levine reshaped incentives for pharmaceutical companies, affecting regulatory strategy at Wyeth, Pfizer, Merck & Co., GlaxoSmithKline, and biotech firms engaged with Biotechnology Industry Organization standards. Manufacturers adjusted labeling practices, pharmacovigilance procedures, and communications with the FDA Center for Drug Evaluation and Research to mitigate tort exposure while maintaining compliance under the Federal Food, Drug, and Cosmetic Act and related Drug Enforcement Administration oversight when applicable. The decision prompted discussions in journals such as The New England Journal of Medicine, Journal of the American Medical Association, and among stakeholders at forums including DIA (Drug Information Association) conferences, influencing litigation funding patterns in product liability and insurance strategies employed by carriers like AIG and Marsh & McLennan Companies.

Subsequent Litigation and Policy Responses

Post-Levine litigation saw varied outcomes in lower federal and state courts, with plaintiffs invoking the decision in suits against companies like AbbVie, Johnson & Johnson, and Abbott Laboratories, while defendants pursued motions invoking preemption and regulatory compliance evidence. Legislative responses included bills discussed in the United States Congress proposing statutory limits on tort remedies or express preemption for FDA-approved labels, debated in committees such as the Senate Committee on Health, Education, Labor, and Pensions and the House Committee on Energy and Commerce. Administrative policy shifts involved FDA guidance documents on labeling changes, citizen petitions submitted by industry trade groups including the Pharmaceutical Research and Manufacturers of America (PhRMA), and executive-branch considerations under administrations including those of George W. Bush and Barack Obama. The doctrinal balance struck in Wyeth v. Levine continues to influence doctrine in subsequent decisions and regulatory rulemaking spearheaded by the Department of Health and Human Services and judicial review in circuits across the United States Court of Appeals.

Category:United States Supreme Court cases